Holen Sie sich die Stockscreener-App
96.30
0.03%
0.0286
Schlusskurs vom Vortag:
$96.27
Offen:
$96.25
24-Stunden-Volumen:
1.17M
Relative Volume:
0.50
Marktkapitalisierung:
$7.30B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-24.38
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+0.32%
1M Leistung:
+1.12%
6M Leistung:
+75.38%
1J Leistung:
+120.17%
1-Tages-Spanne:
$96.25
$96.42
1-Wochen-Bereich:
$96.01
$96.42
52-Wochen-Spanne:
$33.19
$96.42
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
96.29 | 7.30B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-08-25 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus NV stock hits all-time high at 96.29 USD By Investing.com - Investing.com Canada
How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors - Yahoo Finance
Saturn V Capital Management LP Has $11.80 Million Stock Position in Merus N.V. $MRUS - MarketBeat
Is Merus N.V. (2GH) stock included in top ETFs2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
Can Merus N.V. stock outperform in 2025 bull marketQuarterly Growth Report & Capital Efficient Trade Techniques - Newser
Merus N.V. (MRUS): A Bull Case Theory - Finviz
Why institutional investors increase stakes in Merus N.V. (2GH) stockTrade Ideas & Technical Pattern Based Signals - Newser
What makes Merus N.V. (2GH) stock appealing to growth investorsWeekly Trend Recap & High Conviction Buy Zone Picks - Newser
Genmab closes $2.5 billion notes offering to fund Merus acquisition - Investing.com
Genmab closes $2.5 billion notes offering to fund Merus acquisition By Investing.com - Investing.com South Africa
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes - GlobeNewswire Inc.
Sio Capital Management LLC Purchases Shares of 62,719 Merus N.V. $MRUS - MarketBeat
Merus (MRUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Quadrature Capital Ltd Buys New Position in Merus N.V. $MRUS - MarketBeat
Will Merus N.V. (2GH) stock return to pre crash levelsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Can Merus N.V. (2GH) stock hold up in economic slowdownMarket Performance Recap & Risk Controlled Swing Trade Alerts - Newser
Merus N.V. $MRUS Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
What analysts say about Merus NV stockEarnings Volatility Patterns & Free Transform Portfolio With Stocks - earlytimes.in
Merus (NASDAQ:MRUS) VP Harry Shuman Sells 8,300 Shares - MarketBeat
Responsive Playbooks and the MRUS Inflection - news.stocktradersdaily.com
Merus N.V.: VP controller Shuman sells $796k in shares By Investing.com - Investing.com Australia
ETFs investiert in Merus N.V.-Aktien - TradingView
Major Stock Sale Shakes Up Merus! - TipRanks
Merus N.V.: VP controller Shuman sells $796k in shares - Investing.com
Finance Watch: Lilly Toes The $1 Trillion Valuation Line - Citeline News & Insights
Halozyme Therapeutics (HALO): Evaluating Valuation Following New ENHANZE Partnership With Merus - simplywall.st
DNB Asset Management AS Sells 3,706 Shares of Merus N.V. $MRUS - MarketBeat
How cyclical is Merus N.V. (2GH) stock compared to rivalsTrade Ideas & Community Supported Trade Ideas - BỘ NỘI VỤ
Merus, Halozyme enter collaboration, license agreement for petosemtamab - MSN
Is Merus N.V. (2GH) stock positioned for digital growth eraJuly 2025 Trends & Accurate Intraday Trading Signals - moha.gov.vn
MRUS SC14D9C & SEC Filings - Yahoo Finance Australia
Does Merus Licensing Deal Signal a New Growth Phase for Halozyme Therapeutics (HALO)? - simplywall.st
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
Rare NRG1 Fusion Market Research Report 2025-2035 Featuring Merus, Hummingbird Bioscience, Elevation Oncology (Concentra Biosciences), and Shenzhen Salubris PharmaceuticalsResearchAndMarkets.com - Business Wire
Franklin Resources Inc. Has $96.66 Million Position in Merus N.V. $MRUS - MarketBeat
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Why Merus N.V. (MRUS) Crashed On Wednesday - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO - The Malaysian Reserve
Why Merus N.V. (2GH) stock attracts wealthy investorsWeekly Loss Report & High Conviction Trade Alerts - newser.com
Is Merus N.V. (2GH) stock supported by free cash flowQuarterly Trade Report & Weekly Momentum Picks - newser.com
Will Merus N.V. stock split again soonExit Point & Stepwise Trade Signal Guides - newser.com
Merus N.V. $MRUS Shares Acquired by Westfield Capital Management Co. LP - MarketBeat
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
Why Merus N.V. (2GH) stock could be next leader2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Will Merus N.V. stock deliver strong dividend growth2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
How Merus N.V. (2GH) stock reacts to stronger dollarBull Run & Low Drawdown Investment Ideas - newser.com
Will Merus N.V. stock reach Wall Street targetsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
Can Merus N.V. stock maintain growth trajectoryJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
Is Merus N.V. stock a buy for dividend growthPortfolio Performance Report & Stock Market Timing Techniques - newser.com
Can Merus N.V. (2GH) stock test all time highsBear Alert & Daily Price Action Insights - newser.com
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merus N V-Aktie (MRUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Option Exercise |
24.43 |
25,000 |
610,750 |
25,000 |
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):